On Tuesday, August 6, 2019, the Federal Circuit affirmed an International Trade Commission (ITC) decision upholding Finnegan client Ajinomoto’s E. Coli bacteria patent used to produce amino acid. In May 2016, Ajinomoto challenged Korean company CJ CheilJedang Corp.’s imports of E.Coli strains at the ITC. As a result, CJ developed two work-around strains. While the ITC administrative law judge initially ruled that there was no infringement of Ajinomoto’s patents, the full commission’s review found Ajinomoto’s patent claim held up and was infringed by CJ’s two work-around strains. The ITC issued a limited exclusion order against the infringing products and a cease-and-desist order against an American subsidiary, which had an inventory of the infringing products.
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Commentary
World IP Day: EPO Reveals 33% Jump in Cleantech Inventions Over Five Years
April 26, 2024
Award/Ranking
Finnegan Shortlisted for the 2024 Asian Legal Business Japan Law Awards
April 26, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.